Record #40859
Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation
Publisher
Original paper date
Dec 18, 2017
Original DOI
Country
Open access
No
Article type
Citation lifecycle
How this paper is being cited
Pre-retraction
17
Same day
0
Post-retraction
11
% post-retraction
39.3%
~3.5 citations/yr before retraction · ~2.9 citations/yr after
— citing papers
Who is still citing this work
Loading…